Biocom California Appoints New Members to Its Board of Directors and Board of Governors

SAN FRANCISCO, LOS ANGELES & SAN DIEGO–(BUSINESS WIRE)–Biocom California, the association representing the California life science industry, today announced that it has added Amy Butler, Ph.D., president of Biosciences at Thermo Fisher Scientific, to its board of directors and has appointed David H. Crean, Ph.D., managing partner of Coast Bioventures LLC, to its board of governors.

“Drs. Butler and Crean are respected industry leaders who offer strategic insight and expertise that help support our mission, advance key initiatives and accelerate our industry – throughout California and beyond,” said Joe Panetta, president and CEO of Biocom California. “California’s life sciences represent a key economic driver throughout the state, and both Drs. Butler and Crean’s deep-rooted knowledge will help us meet the needs of our member companies in important ways.”

Dr. Butler is the president of Biosciences at Thermo Fisher Scientific, where she has led businesses focused on delivering innovative products and services that support customers in cell and gene therapy, nucleic acid therapeutics, synthetic biology and gene expression profiling, among others. During her 17 years at the company, she has also held leadership roles overseeing Marketing & e-Business and Global Customer Care. She also served as an engagement manager with McKinsey & Co., where she worked predominantly with large pharmaceutical companies on R&D, sales and marketing strategies. Prior to that, Dr. Butler was a developmental neuroscientist at the Salk Institute. She also sits on the Alliance for Regenerative Medicine board of directors.

Dr. Crean has more than 25 years of buy-and sell-side expertise of M&A, partnering and investments within life sciences and healthcare working within strategic biopharma companies, private equity, investment banking and venture capital. He is currently the managing general partner of Coast Bioventures LLC, an emerging life sciences-focused investment fund. In parallel to Coast, he is a venture partner for Suncoast Venture Partners and a limited partner with Mesa Verde Venture Partners, two life sciences funds focused on incubator through early growth-stage companies. Prior to his leadership in venture capital, he was an investment banker and M&A strategic advisor with Objective Capital and Cardiff Advisory. Dr. Crean currently serves in leading boards of director roles for Histogen, Inc., Phoenix Molecular Designs and others. Dr. Crean is also the chairman of the Alzheimer’s Association of San Diego and an active member of the Association for Corporate Growth (ACG), where he served as president for the past two years. He chairs the Biocom California Capital Development Committee.

About Biocom California

Biocom California is the leader and advocate for California’s life science sector. We work on behalf of more than 1,500 members to drive public policy, build an enviable network of industry leaders, create access to capital, introduce cutting-edge STEM education programs and create robust value-driven purchasing programs.

Founded in 1995 in San Diego, Biocom California provides the strongest public voice to research institutions and companies that fuel the local and state-wide economy. Our goal is simple: to help our members produce novel solutions that improve the human condition. In addition to our San Diego headquarters, Biocom California operates core offices in Los Angeles and the San Francisco Bay Area, with satellite offices in Sacramento, Washington, D.C. and Tokyo. Our broad membership benefits apply to biotechnology, pharmaceutical, medical device, genomics and diagnostics companies of all sizes, as well as to research universities and institutes, clinical research organizations, investors and service providers.

For more information on Biocom California, please visit our website at www.biocom.org. Connect with us on LinkedIn, Facebook, and Twitter (@BIOCOMCA).

Contacts

Biocom California Media Contact:
Carolyn Hawley

Canale Communications

(619) 849-5382

[email protected]